A literature that included a small sample of patients reported that in stage IV CRC patients with BRAF V600E mutations who did not use immunotherapy, the proportion of MSI patients was higher among those who survived longer (32), and there is also a study showing that the prognosis of the above two groups is comparable (3). The gene discussed is BRAF; the disease is colorectal carcinoma.